NEW YORK, June 1, 2026, 09:02 (EDT)
- Rezolute was last at $3.30 in premarket trade on Nasdaq, up 4 cents from its prior close.
- Rezolute, Inc. is set to join the Jefferies Global Healthcare Conference, running June 2-4.
- Regulatory worries stick around after Rezolute’s Phase 3 sunRIZE trial failed to hit its main goal. The company pointed to wider glucose-monitoring data as potential support for future plans.
Rezolute Inc. shares ticked up in premarket trading Monday, with the gain coming ahead of a scheduled appearance by company executives at a healthcare event later this week.
The shares were at $3.30, up 4 cents, with the rare-disease drug maker’s market cap around $343 million. This was before the regular Nasdaq open; the exchange lists pre-market hours from 4:00 a.m. to 9:30 a.m. Eastern.
Timing is key. Rezolute is looking to keep investors’ attention on its main drug, ersodetug, after a late-stage trial in congenital hyperinsulinism failed to hit its main target late last year. The rare disorder causes too much insulin and pushes blood sugar to risky lows.
Rezolute, Inc. said management will join the Jefferies Global Healthcare Conference from June 2-4, with plans for fireside chats and one-on ones. These events can shift how investors view a small biotech’s drug pipeline when the next big update is likely to come from regulators, not commercial sales.
Rezolute is focusing on new data from its sunRIZE Phase 3 trial for ersodetug in congenital hyperinsulinism. The company said continuous glucose monitoring showed less time in hypoglycemia across several analyses.
Rezolute chief medical officer Brian Roberts said in May that deeper data review showed “evidence of target engagement, drug activity, and the potential for meaningful therapeutic benefit from ersodetug.” Still, Rezolute said the trial missed the main goal set ahead of the study. Rezolute, Inc.
FDA hasn’t given the green light yet. Rezolute said the regulator pushed it to send in full study reports and analysis data for review, and repeated that it needs adequate and well-controlled evidence before an approval.
Nevan Charles Elam, CEO of Rezolute, said after meeting with the FDA that the agency “did not dismiss sunRIZE outright” even though the program missed its main goal. He said the feedback was early, and Rezolute is still planning for a program update in the back half of 2026. Rezolute, Inc.
Rezolute has some flexibility with its balance sheet, but not a lot. The company ended March with $120.3 million in cash, cash equivalents and marketable securities, down from $167.9 million at June 2025. Net loss for the quarter came in at $16.2 million, less than the $18.9 million loss from a year ago.
Zealand Pharma’s dasiglucagon is up for FDA review for treating congenital hyperinsulinism for up to three weeks, with plans to file for longer use soon. It’s another rare-disease hypoglycemia program in the mix, but it doesn’t work like the others.
Sector moves were quiet. The SPDR S&P Biotech ETF added 74 cents to $136.69 after the open. The iShares Nasdaq Biotechnology ETF was almost flat at $172.18.
The risk is clear. If the FDA asks for more than the current sunRIZE package, Rezolute may have to run another study, gather extra data, or face a longer review. That would mean higher cash burn and push back the schedule. The stock could stay volatile, moving sharply like other small biotech names with a single lead drug.
